TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32967450

Group type: EXPERIMENTAL
Intervention: LithoVue
Number of subjects: 50

Group type: COMPARATOR
Intervention: Uscope PU3022A
Number of subjects: 50
Study: 34749994

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone 1 mg kg‐1
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intermediate-dose dexamethasone 0.3 mg kg‐1
Number of subjects: 88
Study: 32634544

Group type: EXPERIMENTAL
Intervention: Radiomics features from pretreatment 18F-DOPA PET imaging
Number of subjects: 86

Group type: COMPARATOR
Intervention: Patients with unknown MGMT methylation status
Number of subjects: 86
Study: 34609284

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy (RA)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Scoring system based on regression coefficients
Number of subjects: 220
Study: 34824001

Group type: COMPARATOR
Intervention: Manual therapy and lumbar segmental stabilization
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Manual therapy and lumbar segmental stabilization plus specific hip strengthening
Number of subjects: 70
Study: 35057413

Group type: EXPERIMENTAL
Intervention: Capsaicin (CAP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study: 35015038

Group type: EXPERIMENTAL
Intervention: 6-week anticoagulant therapy (n=207)
Number of subjects: 417

Group type: COMPARATOR
Intervention: 3-month anticoagulant therapy (n=210)
Number of subjects: 417
Study: 35373657

Group type: EXPERIMENTAL
Intervention: Local-SC catchment areas
Number of subjects: 20603
Study: 33713371

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus dexamethasone (0.2% ropivacaine plus 0.025% dexamethasone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ropivacaine alone (0.2% ropivacaine)
Number of subjects: 80
Study: 35817072

Group type: EXPERIMENTAL
Intervention: Tixagevimab-cilgavimab
Number of subjects: 1417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1417
Study: 33731163

Group type: EXPERIMENTAL
Intervention: Modern medicine (pirfenidone) plus TCM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Modern medicine plus TCM placebo
Number of subjects: 0
Study: 32546491

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation programme plus TYMO system
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation programme plus Walker View
Number of subjects: 195

Group type: COMPARATOR
Intervention: Traditional rehabilitation programme
Number of subjects: 195
Study: 616973594

Group type: EXPERIMENTAL
Intervention: Combined cabergoline (0.5 g weekly) and metformin (1000 mg daily) for 3 months
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metformin (1000 mg daily) and placebo for 3 months
Number of subjects: 250
Study: 33602710

Group type: EXPERIMENTAL
Intervention: Prescribed exercise regimen
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Hypochlorous acid (HOCl) wound solution
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo wound solution
Number of subjects: 380

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 380
Study: 32282434

Group type: EXPERIMENTAL
Intervention: Intacs and CXL (same session)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intacs followed by CXL (3 months later)
Number of subjects: 150
Study: 35686506

Group type: COMPARATOR
Intervention: Malaysian participants
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: ANZ participants
Number of subjects: 353
Study: 33864830

Group type: EXPERIMENTAL
Intervention: ALA+SFC (100 and 115 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (CNT)
Number of subjects: 15
Study: 32762882

Group type: EXPERIMENTAL
Intervention: Peg‐ IFNα (180 mcg/week) with TDF (300 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: TDF (300 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Peg‐ IFNα (180 mcg/week)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Combination therapy (Peg‐ IFNα and TDF)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monotherapy with Peg‐IFNα
Number of subjects: 67

Group type: COMPARATOR
Intervention: Monotherapy with TDF
Number of subjects: 67
Study: 35610142

Group type: EXPERIMENTAL
Intervention: Locally applied estrogen (LET)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34174455

Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PtDA)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Operated patients
Number of subjects: 193
Study: 33896436

Group type: EXPERIMENTAL
Intervention: Online Family Problem-Solving Therapy (OFPST)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (internet resource comparison)
Number of subjects: 274
Study: 32873678

Group type: EXPERIMENTAL
Intervention: Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: SADI-S
Number of subjects: 183

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 183
Study: 35837991

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glimepiride 2 mg daily
Number of subjects: 23
Study: 34610611

Group type: EXPERIMENTAL
Intervention: Multifunctional cocktail
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 90
Study: 34251886

Group type: EXPERIMENTAL
Intervention: T-Tilt position (15° Trendelenburg and 15° airplane away from the surgical side kidney)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard position
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 138
Study: 33109244

Group type: EXPERIMENTAL
Intervention: Boron compounds (5 mg) twice a day for two weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (200 mg) twice a day for two weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Boron compounds (5 mg) with oleoylethanolamide (200 mg) twice a day for two weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine treatments only (no additional treatment)
Number of subjects: 40
Study: 34487313

Group type: EXPERIMENTAL
Intervention: eHealth app ReMind (10-week program including psychoeducation, strategy-training, and attention retraining)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 62
Study: 32367694

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen at 4 L/min via nasal cannula during exercise
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo air at 4 L/min via nasal cannula during exercise
Number of subjects: 72
Study: 34983478

Group type: EXPERIMENTAL
Intervention: Peer education intervention (4 sessions of 60-min education)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 80
Study: 33992717

Group type: EXPERIMENTAL
Intervention: Once-daily CCTRT at 65 Gy in 26 fractions
Number of subjects: 182

Group type: COMPARATOR
Intervention: Twice-daily CCTRT at 45 Gy in 30 fractions
Number of subjects: 182
Study: 32800971

Group type: EXPERIMENTAL
Intervention: Self-reported movement restriction scale
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physical therapists' interpretation of cervical ROM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Agreement between physical therapists (PTs)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Objective measure of cervical ROM
Number of subjects: 100
Study: 34728032

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte beverage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Plain boiled water
Number of subjects: 15
Study: 32638615

Group type: EXPERIMENTAL
Intervention: Personalized Integrative Therapy (PI Therapy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Personalized Integrative Therapy + Nutritional Supplements (PI Therapy + Supps)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 48
Study: 33036734

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Open radical hysterectomy
Number of subjects: 12
Study: 34081673

Group type: EXPERIMENTAL
Intervention: Community Assessment for Public Health Emergency Response (CASPER)
Number of subjects: 178
Study: 33518729

Group type: EXPERIMENTAL
Intervention: Breathing retraining with chest wall mobilization
Number of subjects: 32

Group type: COMPARATOR
Intervention: Rest for 30 minutes (Control)
Number of subjects: 32
Study: 34351533

Group type: EXPERIMENTAL
Intervention: Engager plus usual care
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 280
Study: 35776254

Group type: EXPERIMENTAL
Intervention: PrEP use stigma
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Disclosure of PrEP use to sexual partner and belief that PrEP prevents HIV
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Fear and shame about people living with HIV
Number of subjects: 307
Study: 35354324

Group type: EXPERIMENTAL
Intervention: Acceptance-Facilitating Intervention (AFI)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 398
Study: 32375651

Group type: EXPERIMENTAL
Intervention: Gum-elastic bougie (GEB)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Endotracheal tube + stylet
Number of subjects: 209
Study: 35947349

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every 4 weeks (Q4W)
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg at weeks 0 and 4 and then every 8 weeks (Q8W)
Number of subjects: 738

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: guselkumab (after crossover from placebo at week 24)
Number of subjects: 738
Study: 34059406

Group type: EXPERIMENTAL
Intervention: Intervention group adolescents watched a video and completed an asthma question prompt list before their visits.
Number of subjects: 359

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 359
Study: 32723804

Group type: EXPERIMENTAL
Intervention: Daprodustat 4 mg once daily
Number of subjects: 271

Group type: COMPARATOR
Intervention: Darbepoetin alfa 10-60 μg once weekly
Number of subjects: 271
Study: 35797441

Group type: EXPERIMENTAL
Intervention: Bioimpedance spectroscopy (BIS)
Number of subjects: 918

Group type: COMPARATOR
Intervention: Tape measurement (TM)
Number of subjects: 918
Study: 34787656

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride 5 mg or 10 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Combination acetaminophen and codeine 500 mg and 8 mg or 1000 mg and 16 mg (1 or 2 tablets) 4 times daily for a maximum of 3 weeks
Number of subjects: 120
Study: 32726431

Group type: EXPERIMENTAL
Intervention: Preemptive therapy (PET)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Older donor age
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Early-onset viremia (within 4 weeks)
Number of subjects: 94
Study: 32682357

Group type: EXPERIMENTAL
Intervention: 20 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 10 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.0625% bupivacaine plus 2 μg/mL of fentanyl
Number of subjects: 81
Study: 34747048

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Training (MICT)
Number of subjects: 81
Study: 33581975

Group type: EXPERIMENTAL
Intervention: Static spacer
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Articulating spacer
Number of subjects: 52
Study: 36424662

Group type: EXPERIMENTAL
Intervention: Accelerated renal replacement therapy (RRT) initiation
Number of subjects: 2927

Group type: COMPARATOR
Intervention: Standard renal replacement therapy (RRT) initiation
Number of subjects: 2927

Group type: EXPERIMENTAL
Intervention: Accelerated RRT initiation
Number of subjects: 2927
Study: 34535644

Group type: EXPERIMENTAL
Intervention: 1000 mg twice a day of berberine ursodeoxycholate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33165938

Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 34822189

Group type: EXPERIMENTAL
Intervention: Intravenous L-ornithine L-aspartate (LOLA) at a dose of 30 g over 24 hours for 5 days, combined with lactulose and rifaximin
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Intravenous L-ornithine L-aspartate (LOLA)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo, lactulose, and rifaximin
Number of subjects: 140
Study: 32416690

Group type: EXPERIMENTAL
Intervention: HGF gene therapy (naked plasmid DNA encoding hepatocyte growth factor)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 35256225

Group type: EXPERIMENTAL
Intervention: Preemptive analgesia (300 mg gabapentin, 200 mg celecoxib, 500 mg acetaminophen 2 hours before surgery)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 34836092

Group type: COMPARATOR
Intervention: 2′FL/LNnT 10g
Number of subjects: 58

Group type: COMPARATOR
Intervention: 2′FL/LNnT 5g
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 32058878

Group type: EXPERIMENTAL
Intervention: Performance feedback on the recollection task
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Patients with psychosis
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study: 33787841

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with mFOLFIRINOX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neoadjuvant treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Precision oncology with genomic and somatic testing
Number of subjects: 0
Study: 32469893

Group type: EXPERIMENTAL
Intervention: Intramuscular electroporation of HIV-MAG DNA vaccine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 33477316

Group type: EXPERIMENTAL
Intervention: Manual therapy + exercise
Number of subjects: 48

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 48
Study: 32276953

Group type: EXPERIMENTAL
Intervention: Brief family psychoeducation (FPE) provided by visiting nurses
Number of subjects: 47

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 47
Study: 36202198

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 300 mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Intravenous zanamivir 600 mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Oral oseltamivir 75 mg
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Hospital Recovery Scale on Day 6
Number of subjects: 488
Study: 34783729

Group type: EXPERIMENTAL
Intervention: Utrecht Work Engagement Scale‐Student (UWES‐S) - exploratory factor analysis with group A
Number of subjects: 898

Group type: EXPERIMENTAL
Intervention: Utrecht Work Engagement Scale‐Student (UWES‐S) - confirmatory factor analysis with group B
Number of subjects: 898
Study: 32418809

Group type: EXPERIMENTAL
Intervention: Anodal transspinal Direct Current Stimulation (tsDCS) at low thoracic level (20 min, 2.5 mA, cathode on shoulder)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 35277038

Group type: EXPERIMENTAL
Intervention: Enzyme-modified oil oral nutritional supplement (EMO-ONS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard triacylglycerol-based ONS product (TAG-ONS) with PERT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both EMO-ONS and TAG-ONS+PERT
Number of subjects: 10
Study: 32574844

Group type: EXPERIMENTAL
Intervention: SCF (12 g/d)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: SCF (12 g/d) + 600 mg/d of calcium
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo + 600 mg/d of calcium
Number of subjects: 240
Study: 36224575

Group type: EXPERIMENTAL
Intervention: Robotic-assisted balance treatment using the Hunova® robotic platform for 3 times a week, for 4 weeks (12 total sessions), 45 min of treatment, in addition to conventional treatment.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional treatment as per daily routine.
Number of subjects: 24
Study: 34836225

Group type: EXPERIMENTAL
Intervention: 770 mg of Tribulus terrestris L. supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 34571001

Group type: EXPERIMENTAL
Intervention: Dynamic Optical Coherence Tomography (D-OCT)
Number of subjects: 50
Study: 32687266

Group type: EXPERIMENTAL
Intervention: Eflapegrastim (13.2 mg, 3.6 mg G-CSF)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg G-CSF)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Eflapegrastim
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Eflapegrastim and Pegfilgrastim
Number of subjects: 237
Study: 36147622

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Enhanced lower limb therapy (ELLT)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy (CRT)
Number of subjects: 192
Study: 35368494

Group type: EXPERIMENTAL
Intervention: mHealth intervention (daily text message for 30 days)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (one-time, face-to-face, brief didactic structured educational session)
Number of subjects: 76
Study: 33259665

Group type: EXPERIMENTAL
Intervention: SLE/TB+ patients
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: SLE/TB+ patients with poorer in-hospital outcomes
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Positive T-SPOT.TB test and lymphocytopenia
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Lymphocytopenia
Number of subjects: 249
Study: 33772557

Group type: EXPERIMENTAL
Intervention: Moderate pain / moderate fatigue
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Mild pain / moderate fatigue
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Moderate pain / mild fatigue
Number of subjects: 193

Group type: COMPARATOR
Intervention: Mild pain / mild fatigue
Number of subjects: 193
Study: 32636425

Group type: EXPERIMENTAL
Intervention: Domestic nano‐hydroxyapatite remineralizing gel
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: In-office ozone therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Combination of domestic remineralizing gel and ozone therapy
Number of subjects: 92
Study: 34460936

Group type: EXPERIMENTAL
Intervention: Intraoperative open lung condition (OL)
Number of subjects: 1480

Group type: COMPARATOR
Intervention: Non-open lung condition (NOL)
Number of subjects: 1480
Study: 34344607

Group type: EXPERIMENTAL
Intervention: People-centred care model (PCCM) including pharmacist-led clinical medication review
Number of subjects: 277

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 277
Study: 34092112

Group type: EXPERIMENTAL
Intervention: Platinum (carboplatin or cisplatin) once every 3 weeks for four cycles
Number of subjects: 410

Group type: COMPARATOR
Intervention: Capecitabine 14 out of 21 days every 3 weeks for six cycles
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Platinum agents
Number of subjects: 410
Study: 36414286

Group type: EXPERIMENTAL
Intervention: CareConekta smartphone application intervention
Number of subjects: 193
Study: 32747351

Group type: EXPERIMENTAL
Intervention: Universal education about healthy nutrition and physical activity, targeted advice for body image concerns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual practice (teacher-delivered curriculum)
Number of subjects: 0
Study: 34898523

Group type: EXPERIMENTAL
Intervention: Combined general-epidural anesthesia (epidural group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: General anesthesia alone (control group)
Number of subjects: 52
Study: 32078885

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No-Training Control (NTC)
Number of subjects: 121
Study: 34437816

Group type: EXPERIMENTAL
Intervention: Harm reduction e‐card (experimental group)
Number of subjects: 1064

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 1064
Study: 33426901

Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores (baseline score cutoff of 28.5)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores (baseline score cutoff of 27.5)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Research Attitudes Questionnaire scores
Number of subjects: 119
Study: 33043350

Group type: EXPERIMENTAL
Intervention: Er: YAG laser irradiation in periodontal pocket after subgingival scaling with ultrasound and hand instruments
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subgingival scaling with ultrasound and hand instruments alone (Control)
Number of subjects: 30
Study: 36415651

Group type: EXPERIMENTAL
Intervention: Paramedic-administered breathlessness management intervention plus usual care
Number of subjects: 13

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 13
Study: 32786188

Group type: EXPERIMENTAL
Intervention: Compression therapy plus education on cellulitis prevention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Education alone (control group)
Number of subjects: 84
Study: 36283713

Group type: EXPERIMENTAL
Intervention: Prone position (group P)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sitting position (group S)
Number of subjects: 64
Study: 33317326

Group type: EXPERIMENTAL
Intervention: Women (gender)
Number of subjects: 4875

Group type: EXPERIMENTAL
Intervention: Women (gender) with DNR order
Number of subjects: 4875

Group type: EXPERIMENTAL
Intervention: Women (gender) without WLST
Number of subjects: 4875

Group type: COMPARATOR
Intervention: Women (gender) with WLST
Number of subjects: 4875